ILMN Stock Forecast: Illumina, Inc. Price Predictions for 2026-2027
The 21 Wall Street analysts covering Illumina, Inc. hold a median 12-month price target of $273 — +41.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Illumina, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (45): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ILMN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ILMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +41.2% from it.
Of the 20 most recent actions, 18 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Citigroup | Maintains | Sell | $113 → $210 |
| 30 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $290 → $275 |
| 30 Oct 2026 | JP Morgan | Maintains | Overweight | $320 → $300 |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Hold | $205 → $300 |
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $210 → $270 |
| 7 Oct 2026 | Barclays | Maintains | Underweight | $160 → $200 |
| 5 Oct 2026 | RBC Capital | Maintains | Outperform | $230 → $310 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $226 → $305 |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | $220 → $300 |
| 28 Sept 2026 | Piper Sandler | Maintains | Overweight | $225 → $305 |
| 9 Sept 2026 | UBS | Upgrade | Buy | $135 → $260 |
| 3 Sept 2026 | Argus Research | Maintains | Buy | $180 → $235 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Hold | $190 → $205 |
| 3 Aug 2026 | Citigroup | Maintains | Sell | $95 → $113 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | $200 → $225 |
| 31 July 2026 | Barclays | Maintains | Underweight | $145 → $160 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $200 → $226 |
| 31 July 2026 | JP Morgan | Maintains | Overweight | $220 → $230 |
| 31 July 2026 | RBC Capital | Maintains | Outperform | $170 → $230 |
| 31 July 2026 | Stifel | Maintains | Buy | $155 → $225 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ILMN.
This page is one stock. Monday covers all of them.
ILMN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ILMN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Illumina, Inc. returned +61.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ILMN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 34.2×
- Price / sales
- 6.6×
- Price / book
- 9.6×
- EV / EBITDA
- 27.4×
Cheaper than 25% of US stocks
Cheaper than 16% of US stocks
Cheaper than 8% of US stocks
Cheaper than 13% of US stocks
- Revenue growth (YoY)
- 4.2%
- Earnings growth (YoY)
- 46.7%
- Gross margin
- 66.1%
- Operating margin
- 19.1%
- Net margin
- 19.7%
Higher than 38% of US stocks
Higher than 74% of US stocks
Higher than 79% of US stocks
Higher than 78% of US stocks
Higher than 81% of US stocks
- Return on equity
- 32.4%
- Return on assets
- 8.3%
- Dividend yield
- —
Higher than 89% of US stocks
Higher than 88% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Illumina, Inc. has a market value of $30.3B and an enterprise value of $31.3B.
Revenue in the twelve months to 31 Mar 2026: $4.4B. The latest quarter grew 4.8% year on year.
Net income over the same four quarters: $853.0M, a 19.4% net margin.
Diluted earnings per share, trailing twelve months: $5.50.
Free cash flow in the twelve months to 31 Mar 2026: $967.0M, after $154.0M of capital spending.
Illumina, Inc. spent $784.0M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: 34.2×; forward P/E: 32.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Illumina, Inc. employs 8,600 people — $511K of revenue per employee.
Data provided by Twelve Data
ILMN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ILMN’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Illumina, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ILMN
What is the ILMN stock price forecast for 2026-2027?
The 21 Wall Street analysts covering Illumina, Inc. have a median 12-month price target of $273, with estimates ranging from $165 to $365. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ILMN stock a buy right now?
Of the 21 analysts covering Illumina, Inc., 10 rate it a Buy, 7 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Illumina, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ILMN?
As at 21 Nov 2026, Illumina, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
Will ILMN stock go up?
No one can know that. What the data says: the median 12-month target from 21 analysts implies +41.2% from the last close, and Ticker Nerd's factor model ranks Illumina, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ILMN stock forecast for 2030?
No analyst covering Illumina, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ILMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $365 over the next 12 months.
How has ILMN stock performed over the past year?
Illumina, Inc. returned +61.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Illumina, Inc. do?
Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics.
About Illumina, Inc.
Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics. Illumina also provides sequencing consumables, instruments, software, and support services that help laboratories generate, interpret, and manage genomic data. The company serves customers including academic institutions, genomic research centers, hospitals, pharmaceutical and biotechnology companies, and clinical laboratories. Headquartered in San Diego, California, and founded in 1998, Illumina plays a central role in making genomic analysis more widely accessible for research and healthcare applications.
CEO Mr. Jacob Thaysen Ph.D. · 8,600 employees · United States · https://www.illumina.com